Calcium Trisodium Glutamate Injection (Ditripentat-HeylAmp.) is a heavy metal chelating agent, mainly used for the treatment of internal contamination by transuranic elements such as plutonium, americium, and curium. This drug promotes the excretion of radioactive metals from the body through urine by forming stable chelates with them.
Precautions for the Use of Calcium Trisodium Glutamate Injection (Ditripentat-HeylAmp.)
Indications
Treatment of known or suspected internal contamination by transuranic elements including plutonium, americium, and curium.
The drug exhibits the optimal effect when used within 24 hours after internal contamination by radioactive elements.
Contraindications and Precautions
Contraindicated in patients allergic to any component of the drug.
Use with caution in patients with severe hemochromatosis.
Contraindicated in patients with specific ocular infections such as herpes simplex virus infection of the eye.
Administration Routes
Intravenous administration is the preferred route (either as a 3-4 minute intravenous push or as an infusion after dilution).
The inhalation route is only applicable to patients with pure inhalational contamination within 24 hours.
Course of treatment: Determined based on the degree of contamination and individual response.
Endogenous Metal Depletion
May cause depletion of essential metals such as zinc, magnesium, and manganese.
The risk increases with higher doses and longer treatment durations.
Preventive measures: Switch to zinc-DTPA therapy after the single initial dose of this drug.
Supplement with zinc-containing minerals if necessary.
Risks of Inhalation Administration
May exacerbate asthma symptoms.
Avoid swallowing sputum after inhalation administration.
Treatment Monitoring for Calcium Trisodium Glutamate Injection (Ditripentat-HeylAmp.)
Radioactivity Assessment
Baseline whole-body counting or biological dosimetry before treatment.
Weekly radioactivity testing of blood, urine, and feces.
Laboratory Tests
Complete blood count with differential.
Blood urea nitrogen and serum electrolytes.
Levels of trace elements such as serum zinc.
Routine urine examination.
Special Monitoring Scenarios
Long-term treatment: Strengthen monitoring of trace element levels.
Pediatric patients: Strict dose control and monitoring.
Inhalation administration: Monitor respiratory symptoms.
Renal impairment: Strengthen monitoring of drug clearance.
Management of Severe Adverse Reactions
Severe metal depletion: Immediately discontinue the drug and supplement with the corresponding minerals.
Allergic reactions: Administer anti-allergic treatment.
Exacerbation of respiratory symptoms: For patients receiving inhalation administration, switch to the intravenous route.
Deterioration of renal function: Consider dialysis treatment.
Guidance on Radiation Protection
Use a dedicated toilet and flush multiple times after use.
Thoroughly clean any contamination from urine or feces.
Wash contaminated clothing separately.
Increase fluid intake to promote urination.
Properly dispose of secretions such as sputum.
Lifestyle Recommendations
Maintain adequate fluid intake.
Avoid contact with potential contaminants.
Lactating women should discontinue breastfeeding.
Conduct regular follow-up monitoring.
